| D80 |
Immunodeficiency with predominantly antibody defects [+]
|
|
| D80.0 |
Hereditary hypogammaglobulinemia
Autosomal recessive agammaglobulinemia (Swiss type)
X-linked agammaglobulinemia [Bruton] (with growth hormone deficiency)
|
| D80.1 |
Nonfamilial hypogammaglobulinemia
Agammaglobulinemia with immunoglobulin-bearing B-lymphocytes
Common variable agammaglobulinemia [CVAgamma]
Hypogammaglobulinemia NOS
|
| D80.2 |
Selective deficiency of immunoglobulin A [IgA]
|
| D80.3 |
Selective deficiency of immunoglobulin G [IgG] subclasses
|
| D80.4 |
Selective deficiency of immunoglobulin M [IgM]
|
| D80.5 |
Immunodeficiency with increased immunoglobulin M [IgM]
|
| D80.6 |
Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia
|
| D80.7 |
Transient hypogammaglobulinemia of infancy
|
| D80.8 |
Other immunodeficiencies with predominantly antibody defects
Kappa light chain deficiency
|
| D80.9 |
Immunodeficiency with predominantly antibody defects, unspecified
|
|
| D81 |
Combined immunodeficiencies [+]
| Excludes 1: |
autosomal recessive agammaglobulinemia (Swiss type) (D80.0)
|
|
|
| D81.0 |
Severe combined immunodeficiency [SCID] with reticular dysgenesis
|
| D81.1 |
Severe combined immunodeficiency [SCID] with low T- and B-cell numbers
|
| D81.2 |
Severe combined immunodeficiency [SCID] with low or normal B-cell numbers
|
| D81.3 |
Adenosine deaminase [ADA] deficiency [+]
|
|
| D81.30 |
Adenosine deaminase deficiency, unspecified
ADA deficiency NOS
|
| D81.31 |
Severe combined immunodeficiency due to adenosine deaminase deficiency
ADA deficiency with SCID
Adenosine deaminase [ADA] deficiency with severe combined immunodeficiency
|
| D81.32 |
Adenosine deaminase 2 deficiency
ADA2 deficiency
Adenosine deaminase deficiency type 2
| Code also |
, if applicable, any associated manifestations, such as:
polyarteritis nodosa (M30.0)
stroke (I63.-)
|
|
| D81.39 |
Other adenosine deaminase deficiency
Adenosine deaminase [ADA] deficiency type 1, NOS
Adenosine deaminase [ADA] deficiency type 1, without SCID
Adenosine deaminase [ADA] deficiency type 1, without severe combined immunodeficiency
Partial ADA deficiency (type 1)
Partial adenosine deaminase deficiency (type 1)
|
|
| D81.4 |
Nezelof's syndrome
|
| D81.5 |
Purine nucleoside phosphorylase [PNP] deficiency
|
| D81.6 |
Major histocompatibility complex class I deficiency
Bare lymphocyte syndrome
|
| D81.7 |
Major histocompatibility complex class II deficiency
|
| D81.8 |
Other combined immunodeficiencies [+]
|
|
| D81.81 |
Biotin-dependent carboxylase deficiency [+]
Multiple carboxylase deficiency
| Excludes 1: |
biotin-dependent carboxylase deficiency due to dietary deficiency of biotin (E53.8)
|
|
|
| D81.810 |
Biotinidase deficiency
|
| D81.818 |
Other biotin-dependent carboxylase deficiency
Holocarboxylase synthetase deficiency
Other multiple carboxylase deficiency
|
| D81.819 |
Biotin-dependent carboxylase deficiency, unspecified
Multiple carboxylase deficiency, unspecified
|
|
| D81.82 |
Activated Phosphoinositide 3-kinase Delta Syndrome [APDS]
p110d-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency [PASLI] disease
| Code also |
, if applicable, any associated manifestations, such as:
bronchiectasis (J47.-)
herpes virus infections (B00.-)
other acute respiratory tract infections (J00-J06; J20-J22)
other infections (A00-B99)
pneumonia (J12-J18)
|
|
| D81.89 |
Other combined immunodeficiencies
|
|
| D81.9 |
Combined immunodeficiency, unspecified
Severe combined immunodeficiency disorder [SCID] NOS
|
|
| D82 |
Immunodeficiency associated with other major defects [+]
| Excludes 1: |
ataxia telangiectasia [Louis-Bar] (G11.3)
|
|
|
| D82.0 |
Wiskott-Aldrich syndrome
Immunodeficiency with thrombocytopenia and eczema
|
| D82.1 |
Di George's syndrome
Pharyngeal pouch syndrome
Thymic alymphoplasia
Thymic aplasia or hypoplasia with immunodeficiency
|
| D82.2 |
Immunodeficiency with short-limbed stature
|
| D82.3 |
Immunodeficiency following hereditary defective response to Epstein-Barr virus
X-linked lymphoproliferative disease
|
| D82.4 |
Hyperimmunoglobulin E [IgE] syndrome
|
| D82.8 |
Immunodeficiency associated with other specified major defects
|
| D82.9 |
Immunodeficiency associated with major defect, unspecified
|
|
| D83 |
Common variable immunodeficiency [+]
|
|
| D83.0 |
Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
|
| D83.1 |
Common variable immunodeficiency with predominant immunoregulatory T-cell disorders
|
| D83.2 |
Common variable immunodeficiency with autoantibodies to B- or T-cells
|
| D83.8 |
Other common variable immunodeficiencies
|
| D83.9 |
Common variable immunodeficiency, unspecified
|
|
| D84 |
Other immunodeficiencies [+]
|
|
| D84.0 |
Lymphocyte function antigen-1 [LFA-1] defect
|
| D84.1 |
Defects in the complement system
C1 esterase inhibitor [C1-INH] deficiency
|
| D84.8 |
Other specified immunodeficiencies [+]
|
|
| D84.81 |
Immunodeficiency due to conditions classified elsewhere
| Code first |
underlying condition, such as:
chromosomal abnormalities (Q90-Q99)
diabetes mellitus (E08-E13)
malignant neoplasms (C00-C96)
|
| Excludes 1: |
certain disorders involving the immune mechanism (D80-D83, D84.0, D84.1, D84.9)
human immunodeficiency virus [HIV] disease (B20)
|
|
| D84.82 |
Immunodeficiency due to drugs and external causes [+]
|
|
| D84.821 |
Immunodeficiency due to drugs
Immunodeficiency due to (current or past) medication
| Use additional |
code for adverse effect if applicable, to identify adverse effect of drug (T36-T50 with fifth or six character 5) |
| Use additional |
code, if applicable, for associated long term (current) drug therapy drug or medication such as: |
| Use additional |
long term (current) drug therapy systemic steroids (Z79.52) |
| Use additional |
other long term (current) drug therapy (Z79.899) |
|
| D84.822 |
Immunodeficiency due to external causes
| Code also |
, if applicable, radiological procedure and radiotherapy (Y84.2)
|
| Use additional |
code for external cause such as: |
| Use additional |
exposure to ionizing radiation (W88) |
|
|
| D84.89 |
Other immunodeficiencies
|
|
| D84.9 |
Immunodeficiency, unspecified
Immunocompromised NOS
Immunodeficient NOS
Immunosuppressed NOS
|
|
| D86 |
Sarcoidosis [+]
|
|
| D86.0 |
Sarcoidosis of lung
|
| D86.1 |
Sarcoidosis of lymph nodes
|
| D86.2 |
Sarcoidosis of lung with sarcoidosis of lymph nodes
|
| D86.3 |
Sarcoidosis of skin
|
| D86.8 |
Sarcoidosis of other sites [+]
|
|
| D86.81 |
Sarcoid meningitis
|
| D86.82 |
Multiple cranial nerve palsies in sarcoidosis
|
| D86.83 |
Sarcoid iridocyclitis
|
| D86.84 |
Sarcoid pyelonephritis
Tubulo-interstitial nephropathy in sarcoidosis
|
| D86.85 |
Sarcoid myocarditis
|
| D86.86 |
Sarcoid arthropathy
Polyarthritis in sarcoidosis
|
| D86.87 |
Sarcoid myositis
|
| D86.89 |
Sarcoidosis of other sites
Hepatic granuloma
Uveoparotid fever [Heerfordt]
|
|
| D86.9 |
Sarcoidosis, unspecified
|
|
| D89 |
Other disorders involving the immune mechanism, not elsewhere classified [+]
| Excludes 1: |
hyperglobulinemia NOS (R77.1)
monoclonal gammopathy (of undetermined significance) (D47.2)
|
| Excludes 2: |
transplant failure and rejection (T86.-)
|
|
|
| D89.0 |
Polyclonal hypergammaglobulinemia
Benign hypergammaglobulinemic purpura
Polyclonal gammopathy NOS
|
| D89.1 |
Cryoglobulinemia
Cryoglobulinemic purpura
Cryoglobulinemic vasculitis
Essential cryoglobulinemia
Idiopathic cryoglobulinemia
Mixed cryoglobulinemia
Primary cryoglobulinemia
Secondary cryoglobulinemia
|
| D89.2 |
Hypergammaglobulinemia, unspecified
|
| D89.3 |
Immune reconstitution syndrome
Immune reconstitution inflammatory syndrome [IRIS]
| Use additional |
code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5) |
|
| D89.4 |
Mast cell activation syndrome and related disorders [+]
| Excludes 1: |
aggressive systemic mastocytosis (C96.21)
congenital cutaneous mastocytosis (Q82.2)
(non-congenital) cutaneous mastocytosis (D47.01)
(indolent) systemic mastocytosis (D47.02)
malignant mast cell neoplasm (C96.2-)
malignant mastocytoma (C96.29)
mast cell leukemia (C94.3-)
mast cell sarcoma (C96.22)
mastocytoma NOS (D47.09)
other mast cell neoplasms of uncertain behavior (D47.09)
systemic mastocytosis associated with a clonal hematologic non-mast cell lineage disease (SM-AHNMD) (D47.02)
|
|
|
| D89.40 |
Mast cell activation, unspecified
Mast cell activation disorder, unspecified
Mast cell activation syndrome, NOS
|
| D89.41 |
Monoclonal mast cell activation syndrome
|
| D89.42 |
Idiopathic mast cell activation syndrome
|
| D89.43 |
Secondary mast cell activation
Secondary mast cell activation syndrome
| Code also |
underlying etiology, if known
|
|
| D89.44 |
Hereditary alpha tryptasemia
| Use additional |
code, if applicable, for: |
| Use additional |
allergy status, other than to drugs and biological substances (Z91.0-) |
| Use additional |
personal history of anaphylaxis (Z87.892) |
|
| D89.49 |
Other mast cell activation disorder
Other mast cell activation syndrome
|
|
| D89.8 |
Other specified disorders involving the immune mechanism, not elsewhere classified [+]
|
|
| D89.81 |
Graft-versus-host disease [+]
| Code first |
underlying cause, such as:
complications of transplanted organs and tissue (T86.-)
complications of blood transfusion (T80.89)
|
| Use additional |
code to identify associated manifestations, such as: |
| Use additional |
desquamative dermatitis (L30.8) |
| Use additional |
diarrhea (R19.7) |
| Use additional |
elevated bilirubin (R17) |
| Use additional |
hair loss (L65.9) |
|
|
| D89.810 |
Acute graft-versus-host disease
|
| D89.811 |
Chronic graft-versus-host disease
|
| D89.812 |
Acute on chronic graft-versus-host disease
|
| D89.813 |
Graft-versus-host disease, unspecified
|
|
| D89.82 |
Autoimmune lymphoproliferative syndrome [ALPS]
|
| D89.83 |
Cytokine release syndrome [+]
| Code first |
underlying cause, such as:
complications following infusion, transfusion and therapeutic injection (T80.89-)
complications of transplanted organs and tissue (T86.-)
|
| Use additional |
code for adverse effect, if applicable, to identify immune checkpoint inhibitors and immunostimulant drugs (T45.AX5) |
| Use additional |
code to identify associated manifestations |
|
|
| D89.831 |
Cytokine release syndrome, grade 1
|
| D89.832 |
Cytokine release syndrome, grade 2
|
| D89.833 |
Cytokine release syndrome, grade 3
|
| D89.834 |
Cytokine release syndrome, grade 4
|
| D89.835 |
Cytokine release syndrome, grade 5
|
| D89.839 |
Cytokine release syndrome, grade unspecified
|
|
| D89.84 |
IgG4-related disease
Immunoglobulin G4-related disease
|
| D89.89 |
Other specified disorders involving the immune mechanism, not elsewhere classified
| Excludes 1: |
human immunodeficiency virus disease (B20)
|
|
|
| D89.9 |
Disorder involving the immune mechanism, unspecified
Immune disease NOS
|
|